You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Financement des régimes fondés sur les données probantes

Les monographies et fiches d’information sur les médicaments et les régimes à l’intention des patients offrent des renseignements sur la posologie et l’administration des traitements contre le cancer.

Elles ne sont fournies qu’à titre indicatif et ne visent pas à remplacer les renseignements posologiques ni les recommandations d’un médecin.

Si vous avez des questions à propos du financement des TS-PBQ, veuillez consulter la Foire aux questions (anglais) de notre site Web.

Découvrez les fiches d’information améliorées sur les régimes à l’intention des patients, élaborées en collaboration avec les conseillers des patients et des familles. Disponible en français.

Regimens

22 Items
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab - As Part of the MATRix Regimen in Newly Diagnosed, Previously Untreated PCNSL
May 2019
Cancer Type: Gastrointestinal, Pancreas     
Intent: Adjuvant
May 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Oxaliplatin - Adjuvant Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Oxaliplatin - With Surgery for Curative Intent for CRC SBAC Pts with Resectable or Potentially Resectable Liver Mets
Evidence Building Program
    Oxaliplatin (EBP) - Colorectal Cancer Patients with Resectable or Potentially Resectable Extrahepatic Metastases
Evidence Building Program
    Oxaliplatin (EBP) - Supplemental 1
Evidence Building Program
    Oxaliplatin (EBP) - Supplemental 2
Aug 2019
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Adjuvant, Palliative
Jun 2019
Cancer Type: Genitourinary, Bladder / Urothelial     
Intent: Palliative
Jun 2019
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Jun 2019
Cancer Type: Gastrointestinal, Colorectal     
Intent: Neoadjuvant
Aug 2019
Cancer Type: Gastrointestinal, Hepatobiliary / Liver / Bile Duct     
Intent: Palliative
Jun 2019
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Nov 2019
Cancer Type: Gastrointestinal, Esophagus     
Intent: Adjuvant, Palliative
Jun 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Oxaliplatin - Second Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Oxaliplatin - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Bevacizumab (Biosimilar) - First Line - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Aug 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Oxaliplatin - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for First Line Metastatic Colorectal Small Bowel or Appendiceal Cancer
Aug 2019